Drug
Gaboxadol clinical trials
Also written MK0928 and OV101.
- studies test it
- 17
- open now
- 0
- in phase 3
- 11
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2004 (5)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 2 |
| 2008 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 5
- Phase 3
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 1
H. Lundbeck A/S (10) · Ovid Therapeutics Inc. (3) · Healx AI (2) · Craig Erickson (1) · Healx Limited (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gaboxadol is read from its arms, and is right about nine times in ten.
Testing it · 17
- Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)CompletedPhase 2Craig EricksonNCT06334419Written as Gaboxadol
- A Study in Adults and Adolescents With Angelman Syndrome (STARS)CompletedPhase 2Healx AINCT02996305Written as OV101 Regimen 1
- An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman SyndromeTerminatedPhase 3Healx AINCT03882918Written as OV101
- A Study of OV101 in Individuals With Fragile X SyndromeCompletedPhase 2Ovid Therapeutics Inc.NCT03697161Written as OV101 (gaboxadol)
- A Study of OV101 in Individuals With Angelman Syndrome (AS)CompletedPhase 3Ovid Therapeutics Inc.NCT04106557Written as Gaboxadol
- Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40WithdrawnPhase 2Healx LimitedNCT04823052Written as Gaboxadol (HLX-0206)
- Single Dose Pharmacokinetic (PK) StudyCompletedPhase 1Ovid Therapeutics Inc.NCT03109756Written as OV101
- Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00095043Written as MK0928, gaboxadol
- Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00094627Written as gaboxadol
- Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00102167Written as gaboxadol
- An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00103818Written as gaboxadol
- Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive DisorderCompletedPhase 2H. Lundbeck A/SNCT00807248Written as Gaboxadol 5 mg
- A Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209846Written as Gaboxadol
- A Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209963Written as Gaboxadol
- A Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209924Written as Gaboxadol
- A Prospective Open-Label Extension Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209950Written as Gaboxadol
- A Prospective Active-Reference Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209937Written as Gaboxadol
Codes
What other systems call gaboxadol · ClinicalTrials.gg INT002629
- MeSH (NLM) C015542gaboxadolConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K1M5RVL18SGABOXADOLConfirmed FDA, NLM, Wikidata
- Wikidata Q4130924gaboxadolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72791GaboxadolOne source FDA
- DrugBank DB06554One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C015542 | gaboxadol | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K1M5RVL18S | GABOXADOL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4130924 | gaboxadol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72791 | Gaboxadol | One source FDA |
| DrugBank | DB06554 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.